Post

New research · Ophthalmology
Retina (Philadelphia, Pa.) · 3d
Randomized trialRetina (Philadelphia, Pa.) · 2026

Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

Parul Yadav, Shakha, Sanjay Mishra … Rajpal Vohra
Read paper
OphthalmologyRandomized trial

Topical difluprednate led to complete subretinal fluid resolution far more often than observation.

Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

Parul Yadav … Rajpal Vohra
Retina (Philadelphia, Pa.) · 2026
Purpose

To evaluate the efficacy and safety of topical Difluprednate ophthalmic emulsion 0.05% in chronic Central Serous Chorioretinopathy (cCSCR) and compare its outcomes with oral eplerenone and observation.

Methods

This pilot open-label randomised controlled trial included patients with cCSCR of ≥3 months' duration or relapsing cases with subfoveal or juxtafoveal leakage on angiography.

n = 53 adults
Results

difluprednate cleared retinal fluid completely in most patients, far outperforming no treatment

90%
Difluprednate
45%
Eplerenone
23%
Observation
More results

The difluprednate group showed significantly greater reductions in subfoveal choroidal thickness (subfoveal choroidal thickness) and improvements in 3-mm microperimetry thresholds compared with the observation group (p = 0.012 and p = 0.022, respectively).

More results

It also demonstrated the largest decrease in central macular thickness, although this was not statistically significant (p = 0.19).

Ocular hypertension developed in 30% of difluprednate-treated eyes and was controlled with topical antiglaucoma medication.

“
Conclusion · 1 of 2

Topical difluprednate produced superior anatomical and functional improvements in SRF resolution, subfoveal choroidal thickness reduction, and retinal sensitivity within 3-mm when compared with oral eplerenone and observation.

Conclusion · 2 of 2

Thus, with a manageable safety profile, it may serve as an effective therapeutic option for cCSCR.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving